#1 Clinical Trials Search in Europe

Lebrikizumab

Lebrikizumab is an investigational drug being studied in clinical trials for the treatment of asthma and atopic dermatitis. This article summarizes key information from multiple clinical trials evaluating the safety and efficacy of lebrikizumab in patients with these conditions. The trials are assessing different dosing regimens, administration methods, and patient populations to determine the optimal use of this potential new therapy.

Table of Contents

What is Lebrikizumab?

Lebrikizumab is a medication being studied for the treatment of various inflammatory conditions, primarily atopic dermatitis (also known as eczema) and asthma. It is a type of drug called a monoclonal antibody, which means it’s a laboratory-made protein that targets specific molecules in the body[1][2]. Lebrikizumab is also known by other names such as LY3650150 and DRM06[3].

Conditions Treated by Lebrikizumab

Lebrikizumab is primarily being investigated for two main conditions:

  • Atopic Dermatitis (Eczema): This is a chronic skin condition characterized by itchy, inflamed skin. Lebrikizumab is being studied in patients with moderate-to-severe atopic dermatitis who haven’t responded well to other treatments[4].
  • Asthma: Lebrikizumab has also been studied in patients with mild to moderate asthma, as well as those with uncontrolled asthma despite using other medications[1][2].

How Lebrikizumab Works

Lebrikizumab works by targeting a specific protein in the body called interleukin-13 (IL-13). IL-13 is involved in causing inflammation in conditions like atopic dermatitis and asthma. By blocking IL-13, lebrikizumab aims to reduce inflammation and improve symptoms of these conditions[4].

How Lebrikizumab is Administered

Lebrikizumab is given as a subcutaneous injection, which means it’s injected just under the skin. In clinical trials, it has been administered in various ways:

  • Using a pre-filled syringe with a needle safety device[5]
  • Using an autoinjector (a device that automatically injects the medication)[6]
  • Using a pen device (currently being studied for ease of use)[7]

The frequency of injections varies depending on the study, but it’s often given every 2 or 4 weeks[4].

Clinical Trials and Effectiveness

Lebrikizumab has shown promising results in clinical trials for both atopic dermatitis and asthma:

  • For Atopic Dermatitis: Studies have looked at improvements in skin symptoms using measures like the Eczema Area and Severity Index (EASI) and the Investigator’s Global Assessment (IGA). Many patients have shown significant improvement in their skin condition after treatment with lebrikizumab[4][8].
  • For Asthma: Trials have measured improvements in lung function and reduction in asthma exacerbations (sudden worsening of asthma symptoms). Lebrikizumab has shown potential in improving these outcomes in some patients[1][2].

Potential Side Effects

As with any medication, lebrikizumab may cause side effects. Clinical trials are carefully monitoring for any adverse events. Common side effects observed in studies include:

  • Injection site reactions (redness, pain, or swelling where the injection is given)
  • Upper respiratory tract infections
  • Headache

It’s important to note that the full safety profile of lebrikizumab is still being studied[9].

Ongoing Research

Research on lebrikizumab is ongoing, with several studies currently in progress. These studies are looking at:

  • Long-term safety and effectiveness[4]
  • Use in different patient populations, including those with darker skin tones[3]
  • Comparison with other treatments for atopic dermatitis[8]
  • Different methods of administration to improve ease of use[7]

As research continues, we may learn more about how lebrikizumab can be used to help patients with atopic dermatitis and asthma.

Aspect Details
Drug Name Lebrikizumab (also known as LY3650150, DRM06)
Conditions Studied Asthma, Atopic Dermatitis (Eczema)
Administration Method Subcutaneous injection
Dosing Frequency Every 4 weeks in most trials
Key Outcome Measures Asthma exacerbation rate, lung function (FEV1), EASI score, IGA score, pruritus reduction
Trial Durations Ranging from 16 weeks to 104 weeks
Patient Populations Adults and adolescents with moderate-to-severe asthma or atopic dermatitis
Safety Assessments Adverse events, laboratory tests, anti-drug antibodies
Quality of Life Measures DLQI, CDLQI, AQLQ(S), POEM
Comparators Placebo, different doses of lebrikizumab

FAQ

  • What conditions is lebrikizumab being studied to treat? Lebrikizumab is being studied in clinical trials for the treatment of asthma and atopic dermatitis (also known as eczema).
  • How is lebrikizumab administered? Lebrikizumab is administered as a subcutaneous (under the skin) injection. Various trials are studying different administration methods including pre-filled syringes, autoinjectors, and pens.
  • What are some of the main outcomes being measured in the lebrikizumab trials? Key outcomes include reduction in asthma exacerbations, improvement in lung function, reduction in eczema severity and extent, reduction in itch, and improvement in quality of life measures.
  • How long do the lebrikizumab clinical trials typically last? The duration varies, but many of the trials last 52 weeks (1 year) or longer to assess both short-term and long-term effects of the treatment.
  • Are there any known side effects of lebrikizumab from the clinical trials? The trials are ongoing to evaluate the safety profile. Common methods to assess safety include monitoring for adverse events, laboratory tests, and development of anti-drug antibodies.

Ongoing Clinical Trials on Lebrikizumab

  • Long-Term Safety and Efficacy of Lebrikizumab in Children and Adolescents With Moderate-to-Severe Atopic Dermatitis

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Poland Spain

  • A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

    Recruiting

    3 1 1
    Investigated drugs:
    Bulgaria Germany Italy Poland Spain

  • Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Denmark Finland Germany Hungary +5

  • Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • A Study of Lebrikizumab for Adults and Adolescents with Moderate to Severe Atopic Dermatitis to Evaluate Effects on Eczema and Skin Barrier Function

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Sweden

  • Study of Lebrikizumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis to Understand How the Medicine Works

    Not yet recruiting

    3 1 1 1
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Denmark France Italy Spain Sweden

  • Study on the Effectiveness and Safety of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Germany The Netherlands

  • Study of Lebrikizumab and Mometasone Furoate for Adults with Perennial Allergic Rhinitis

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Poland

  • Study on the Long-term Safety and Effectiveness of Lebrikizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Germany Poland

Glossary

  • Atopic Dermatitis: A chronic inflammatory skin condition characterized by itchy, dry, and inflamed skin. Also known as eczema.
  • Subcutaneous: Underneath the skin. Lebrikizumab is administered via subcutaneous injection.
  • Exacerbation: A worsening of symptoms or increase in severity of a disease. In asthma, this often refers to an asthma attack.
  • FEV1: Forced Expiratory Volume in 1 second. A measure of lung function used to assess asthma severity and treatment effectiveness.
  • EASI: Eczema Area and Severity Index. A tool used to measure the extent and severity of atopic dermatitis.
  • IGA: Investigator's Global Assessment. A scale used to evaluate the overall appearance and severity of skin conditions like atopic dermatitis.
  • Pruritus: Itching. A common and often distressing symptom of atopic dermatitis.
  • DLQI: Dermatology Life Quality Index. A questionnaire that measures the impact of skin conditions on a person's quality of life.
  • Placebo: An inactive substance used as a control in clinical trials to compare against the effects of the investigational drug.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and excreted.

References

  1. https://clinicaltrials.gov/study/NCT02104674
  2. https://clinicaltrials.gov/study/NCT01545440
  3. https://clinicaltrials.gov/study/NCT05372419
  4. https://clinicaltrials.gov/study/NCT05149313
  5. https://clinicaltrials.gov/study/NCT02486809
  6. https://clinicaltrials.gov/study/NCT04840901
  7. https://clinicaltrials.gov/study/NCT06444165
  8. https://clinicaltrials.gov/study/NCT05369403
  9. https://clinicaltrials.gov/study/NCT06243198